{"id":6065,"date":"2014-02-25T12:09:00","date_gmt":"2014-02-25T12:09:00","guid":{"rendered":"http:\/\/www.pharma-mkting.com\/public-citizen-petitions-fda-to-add\/"},"modified":"2019-02-21T01:16:49","modified_gmt":"2019-02-21T01:16:49","slug":"public-citizen-petitions-fda-to-add","status":"publish","type":"post","link":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/blog\/public-citizen-petitions-fda-to-add\/","title":{"rendered":"Public Citizen Petitions FDA to Add a Black Box Warning to Low-T Drug Labeling"},"content":{"rendered":"
\n<\/div>\n
\n<\/a><\/div>\n

Public Citizen today called on the U.S. Food and Drug Administration (FDA) to immediately add a black box warning about the increased risks of heart attacks and other cardiovascular dangers to the product labels of all testosterone-containing drugs available in the U.S. (find the petition here<\/a>).<\/p>\n

A black box warning is the strongest warning that the FDA requires, and signifies that medical studies indicate that the drug carries a significant risk of serious or even life-threatening adverse effects.<\/p>\n

\n<\/div>\n

FDA stated on Jan. 31 that it \u201chas not concluded that FDA-approved testosterone treatment increases the risk of stroke, heart attack, or death.\u201d<\/p>\n

\u201cIn the face of \u2026 accumulating evidence [see, for example, “Testosterone Therapy Tied to Heart Risks<\/a>“], this statement is reckless and is a betrayal of the FDA\u2019s role as an agency in the U.S. Public Health Service,\u201d said Dr. Sidney Wolfe, founder and senior adviser of Public Citizen\u2019s Health Research Group. \u201cIt is quite clear that testosterone treatment increases the risks of cardiovascular diseases, including heart attacks.\u201d<\/p>\n

\u201cUnless the FDA immediately begins to provide strong, adequate black-boxed warnings about the risks of heart attacks and other cardiovascular diseases, the continuing toll of heart attacks, many in people who are not even candidates for testosterone, will continue,\u201d Wolfe said. \u201cAt the present rate of prescribing, almost 13,000 prescriptions a day are filled for testosterone products in this country. Each day of delay of the black box warning ensures much more exposure, too often for men who cannot benefit from the drug but will only be exposed to its risks.\u201d<\/p>\n

Many of the drugs Public Citizen petitioned FDA to remove from the market or cited as “risky” have subsequently been removed — mostly within 7 years of the petition. This has lead to Wolfe’s “Seven-year Rule for Safer Prescribing.” Read on\u2026<\/p>\n

<\/a>Wolfe’s 7-year Rule:<\/p>\n

\n“You should wait at least seven years from the date of release to take any new drug unless it is one of those rare \u2018breakthrough\u2019 drugs that offers you a documented therapeutic advantage over older proven drugs. New drugs are tested in a relatively small number of people before being released, and serious adverse effects or life-threatening drug interactions may not be detected until the new drug has been taken by hundreds of thousands of people. A number of new drugs have been withdrawn within their first seven years after release. Also, warnings about serious new adverse reactions have been added to the labelling of a number of drugs, or new drug interactions have been detected, usually within the first seven years after a drug\u2019s release.”<\/p>\n\n\n\n\n
<\/a><\/td>\n<\/tr>\n
Column 3 is the date that Public Citizen warned its constituents.
\n Column 2 is the date FDA removed the drug from the market.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Drugs that have boxed warnings are not permitted to have reminder ads<\/a>, which mention the pharmaceutical brand name but not the indication or medical condition it treats. Since the possibility of life-threatening adverse events must be included in the major statement of regular direct-to-consumer (DTC) ads, drugs with such black box warnings often — but not always — cease to be advertised on TV.<\/p>\n

In the case of AbbVie’s Androgel, however, ceasing DTC advertising may not affect its leading market share especially because of the success of its “Drive for Five” unbranded campaign, which urges men to know their testosterone (T) levels, in addition to lipid, BP, blood sugar and PSA numbers. An animated “gear box” that shifts from high cholesterol (first gear) to high blood pressure (second gear) to high blood sugar (third gear) to high PSA (four gear) and, finally, to low testosterone (fifth gear) represents the goals of this award-winning campaign (read “AbbVie’s “Drive for Five” Campaign: Innovative, Derivative, and Conflictive?<\/a>“).<\/p>\n

My “black gear box” rendering at the top of this post adds a 6th gear: Heart Attack!<\/p>\n\n\n\n\n\n
The Seven Year Drug Ban Solution<\/td>\n<\/tr>\n
<\/td>\n<\/tr>\n
\n
\n\"Sydney
\nIn this 1-minute audio snippet, Sydney Wolfe<\/b>, MD, formerly head of Public Citizen, explains why you should wait at least seven years from the date of release to take any new drug unless it is one of those rare \u2018breakthrough\u2019 drugs that offers you a documented therapeutic advantage over older proven drugs. <\/p>\n

Your browser does not support the audio element. Upgrade your browser to one that does<\/p>\n

For more about Wolfe’s solutions, read:
\n<\/p>\n